Abstracts tagged "Animal Model"

Abstract Number: 1191 • ACR Convergence 2025
Effect of ER Stress Inhibition With 4-Phenylbutyric Acid on Disease Phenotype in a Mouse Model of Myositis
Alfredo Guzman, Elizabeth Bagley, Rita Spathis, Madison King, Kanneboyina Nagaraju and Melissa Morales, Binghamton University, Johnson City, NY
Background/Purpose: Dysregulation of the ER stress and interferon (IFN) pathways play a major role in the pathophysiology of autoimmune myositis. Upregulation of ER stress markers…
Abstract Number: 0934 • ACR Convergence 2025
The Use Of Preclinical Models To Understand Drivers Of Lupus Pathogenesis
Arielle Glatman Zaretsky¹, Carley Tasker¹, Pablo Abreu¹, Ciara Torres², Li-Hong Ben¹, Scott MacDonnell¹, Andre Limnander¹ and Jamie Orengo¹, ¹Regeneron, Tarrytown, NY, ²Regeneron, Tarrytown
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic, multisystem autoimmune disease with a prevalence of 1.4-15.13/100,000 adults globally. SLE is highly heterogenous and can involve…
Abstract Number: 0052 • ACR Convergence 2025
Profiling of MT-3534, a Humanized Monoclonal Antibody Targeting Peptidylarginine Deiminase 4, as a Candidate Drug for the Treatment of RA
Hisae Niki¹, Akitoshi Nishizawa², Yuuichi Ono¹, Makoto Yamazaki¹, Satoshi Takanashi³, Keiko Yoshimoto⁴, Mitsuhiro Akiyama³, Tsutomu Takeuchi⁵ and Yuko Kaneko⁴, ¹Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan, ²Mitsubishi Tanabe Pharma Corporation, Fujisawa, Kanagawa, Japan, ³Keio University School of Medicine, Tokyo, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ⁵Saitama Medical University and Keio University, Tokyo, Japan
Background/Purpose: Although the management of rheumatoid arthritis (RA) has been remarkably improved, there are still patients who have not responded to existing targeted drugs that…
Abstract Number: 1003 • ACR Convergence 2025
Potent Engineering of Polyfunctional CD8+ T Cells by a Novel In Vivo CAR mRNA Product Candidate (CPTX2309) in a Targeted Lipid Nanoparticle (tLNP) Utilizing CellSeekerTM Technology
Yan Zhang¹, Brittany Ross¹, Aditi Upadhye¹, Diana Galvan¹, Shaun E Grosskurth¹, Yanjie Bao¹, Romina Riener¹, Annabel Wang¹, Aric Frantz¹, Gregor B Adams¹, Michael Rosenzweig¹, Ramin Farzaneh-Far¹, Priya Karmali¹, Adrian I Bot¹, Carl June² and Haig Aghajanian¹, ¹Capstan Therapeutics, San Diego, CA, ²University of Pennsylvania, Philadelphia, PA
Background/Purpose: A major objective in autoimmunity is immune reset, requiring autoreactive B cell depletion in tissues. We designed an in vivo CAR product candidate (CPTX2309)…
Abstract Number: 0935 • ACR Convergence 2025
Oral Antibiotic Treatment Reduces Anxiety in a Murine Model of Neuropsychiatric Manifestations of Systemic Lupus Erythematosus
Cecilia Stumpf¹, Brianna Thompson², Vanessa Manada De Lobos² and Carla Marie Cuda³, ¹Northwestern University, Elmhurst, IL, ²Northwestern University, Chicago, ³Northwestern University, Chicago, IL
Background/Purpose: Unclear mechanisms underlying diffuse NPSLE (anxiety, cognitive dysfunction) lead to the devastating impact of this disease on patients’ health-related quality-of-life. Dysbiosis of gut microbiota…
Abstract Number: 0050 • ACR Convergence 2025
TL1A expression is upregulated in rheumatic diseases and anti-TL1A antibody reduces disease symptoms and pathological changes in rat collagen-induced arthritis
Preeyam Patel¹, Matthew Siegel², Emily Lewis³, David Giles³, Justin LaFountaine³, Joshua Friedman³ and Andy Spencer³, ¹Spyre Therapeutics, Waltham, ²Spyre Therapeutics, Menlo Park, CA, ³Spyre Therapeutics, Waltham, MA
Background/Purpose: The development of disease-modifying anti-rheumatic drugs (DMARDs) has reduced disease activity in patients living with rheumatic diseases. Despite this, there is continued unmet need…
Abstract Number: 1806 • ACR Convergence 2025
Sex differences in knee joint microbial DNA of C57BL/6 mice and the effect of cross-sex microbiome transplantation
Veera Durga Vaishnavi Kurra¹, Ausitn Lopez², Aleksander Szymczak³, Gabriella Dyson³, Pratibha Dube⁴, Padmaja Mehta-d'Souza² and Matlock Jeffries³, ¹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, Edmond, OK
Background/Purpose: Recent studies have suggested an association between the gut microbiome and osteoarthritis. We have previously shown that the joint microbiome is derived at least…
Abstract Number: 0999 • ACR Convergence 2025
Myositis Induced by Histidyl-Transfer tRNA Synthetase is Exacerbated by Membranopathy and Suppressed by Regulatory T Cells
Samantha Coss¹, Nicholas Young², Shane Bruckner³, Braden Zeno⁴, Gianni Giarrano⁵, Hannah Bulgart⁶, Paula Clemens⁷, Jisna Paul², Chester V. Oddis⁸, noah weisleder⁹, Dana Ascherman⁸ and Wael Jarjour¹⁰, ¹Nationwide Children's Hospital, Columbus, OH, ²Division of Rheumatology and Immunology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, Columbus, OH, ³OSU, Columbus, OH, ⁴Ohio State University, upper arlington, OH, ⁵Division of Rheumatology, Nationwide Children's Hospital, Columbus, OH, ⁶Department of Molecular and Cellular Biochemistry, University of Kentucky College of Medicine, Lexington, KY, ⁷Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁸University of Pittsburgh, Pittsburgh, PA, ⁹University of Kentucky, Lexington, KY, ¹⁰The Ohio State University, Columbus, OH
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of autoimmune disorders targeting muscle as well as extra-muscular organs. Among the most common autoantibodies associated…
Abstract Number: 0933 • ACR Convergence 2025
Spatial Transcriptomics Reveal Altered Immune Dynamics Regulating Placental Development In a Humanized-TLR8 Mouse Model of Spontaneous Anti-Phospholipid Antibody Induced Pregnancy Loss
Yunwei Xia¹, Paul Hoover², Arnon Arazi³ and Anne Davidson¹, ¹Feinstein Institutes for Medical Research, Manhasset, NY, ²Brigham and Women's Hospital, Boston, MA, ³Feinstein Institutes for Medical Research, Acton, MA
Background/Purpose: TLR8 has been implicated in adverse outcomes of human pregnancy. We previously reported a mouse model of spontaneous aPL-induced pregnancy loss in Sle1 mice…
Abstract Number: 0049 • ACR Convergence 2025
Enhanced Src Homology Region 2 Domain-containing Phosphatase 1 Activity Ameliorates Murine Inflammatory Arthritis Through the Innate Immune System
Jun Li, Katalin Mikecz and Adrienn Markovics, Rush University Medical Center, Chicago
Background/Purpose: Src homology region 2 domain-containing phosphatase 1 (SHP-1) is a cytoplasmic protein tyrosine phosphatase expressed in hematopoietic cells (PMID9069265). SHP-1 is a key negative…
Abstract Number: 1804 • ACR Convergence 2025
Pharmacology of LEVI-04, a novel treatment for OA
Simon Westbrook¹ and Kerry af Forselles², ¹Levicept Ltd, Sandwich, United Kingdom, ²Levicept, Sandwich, United Kingdom
Background/Purpose: LEVI-04 is a novel fusion protein comprising the extracellular domain of p75 neurotrophin receptor (p75NTR) coupled to IgG1 Fc, being developed for the treatment…
Abstract Number: 0976 • ACR Convergence 2025
LMPTP Drives Fibrosis in Systemic Sclerosis via TGF-beta Signaling Activation
Yuan Zhan¹, Colton Sanders², Michael Diaz², Jinmin Miao³, Arminja Kettenbach⁴, Zhong-Yin Zhang⁵, Paul Wolters⁶, Francesco Boin⁷, Stephanie Stanford² and Nunzio Bottini⁸, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²University of California San Diego, San Diego, CA, ³Purdue University, West Lafayette, IN, ⁴Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁵Purdue University, Department of Medicinal Chemistry and Molecular Pharmacology, West Lafayette, IN, ⁶University of California San Francisco, San Francisco, CA, ⁷Cedars-Sinai Medical Center, Beverly Hills, CA, ⁸Cedars Sinai Medical Center, Beverly Hills, CA
Background/Purpose: The identification of effective and safe anti-fibrotic agents is a critical unmet need in systemic sclerosis (SSc). Although fibrosis in SSc is driven by…
Abstract Number: 0907 • ACR Convergence 2025
Cross-Species Cellular Mapping and Humanization of Fcγ Receptors to Advance Antibody Modeling
Karel Van Damme¹, Dorine Sichien², Katrien Van der Borght³, Sofie Van Gassen³, Elisabeth De Leeuw³, Victor Bosteels⁴, Joseph Jorssen⁵, Seppe De Winter⁶, Alan Korman⁷, Fabio Benigni⁸, Davide Corti⁸, Ariane Morel⁹, Eric Vivier⁹, Hamida Hammad³, Dirk Elewaut¹⁰, Fabiane Sonego¹¹, Kader Thiam¹¹, Sofie Voet², bianca Balbino¹² and Bart Lambrecht³, ¹Ghent University, Ghent, ²argenx, Ghent, Belgium, ³Ghent University, Ghent, Belgium, ⁴The Francis Crick Institute, London, United Kingdom, ⁵Liège Université, Liege, Belgium, ⁶KU Leuven, Leuven, Belgium, ⁷Vir Biotechnology, San Francisco, ⁸Vir Biotechnology, Bellinzona, Switzerland, ⁹Innate Pharma, Marseille, France, ¹⁰VIB Center for Inflammation Research, and Ghent University Hospital, Department of Rheumatology, Ghent, Belgium, ¹¹genOway, Lyon, France, ¹²argenx, Gent, Belgium
Background/Purpose: Fc receptors mediate the effector functions of antibodies by linking adaptive and innate immunity. Immunoglobulin G (IgG), the most abundant antibody in circulation and…
Abstract Number: 0009 • ACR Convergence 2025
MRT-6160, a VAV1-Directed Molecular Glue Degrader, Attenuates T and B Cell Effector Functions and Inhibits Disease Progression in a Spontaneous MRL-Faslpr Mouse Model
Adam Cartwright¹, Lucas Gyger¹, Foram Desai², Shailee Vora², Anna Kostikova¹, Xudong Wang², Peter Trenh², Katie May², Sophia Nguyen², Chris King², Daniel Lam², Xavi Lucas¹, Mary Zlotosch², Elisa Liardo¹, Daric Wible², Ilaria Lamberto², Bradley Demarco², Debora Bonenfant¹, Sharon Townson², Eswar Krishnan², Filip Janku², John Castle¹, Laura McAllister¹, Alison Paterson² and Marisa Peluso², ¹Monte Rosa Therapeutics, Basel, Switzerland, ²Monte Rosa Therapeutics, Boston, MA
Background/Purpose: VAV1, an immune cell restricted guanine nucleotide exchange factor (GEF) and scaffolding protein, plays a critical role in mediating T- and B-cell receptor activity.…
Abstract Number: 1803 • ACR Convergence 2025
Patching of Damaged Meniscus and Cartilage of Osteoarthritic Animals by MM-II, a Dispersion of Empty Large Multilamellar Liposomes
Roni Wechsler and Rany Rotem, Moebius Medical, Tel Aviv, Israel
Background/Purpose: Cartilage wear in knee osteoarthritis (KOA) is linked to reduced boundary lubrication. Occasionally, the meniscus also wears out in KOA, potentially accelerating the disease.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].